Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Jiménez-Urbieta, Haritz; Gago, Belén; Riva, Patricia de la; Delgado-Alvarado, Manuel; Marı́n, Concepció; Rodriguez-Oroz, María C.

doi:10.1016/j.neubiorev.2015.07.010

Cited by 39 publications

(44 citation statements)

References 372 publications

(470 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated that dopaminergic medications influence hallucinations in PD and that they are associated with increased age and longer disease duration [23] [24] [25]. In this present study, hallucinations were associated with increased age and longer disease duration, which is consistent with the current literature.…”

Section: Discussionsupporting

confidence: 92%

Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

Sisniega¹,

Madhusudhan²,

Rahmani³

et al. 2017

APD

View full text Add to dashboard Cite

Background: Compulsive behavior, dyskinesias, motor fluctuations, and hallucinations are common Parkinson's disease (PD) medication side effects.These are yet to be examined in relation to race and level of education. The goal of this analysis was to identify socioeconomic or clinical variables that are associated with compulsive behavior, dyskinesias, motor fluctuations, and hallucinations in patients in a safety-net hospital. Methods: A movement disorder patient database containing 452 patients with idiopathic PD was analyzed for differences in PD medication side effects using univariate and multivariate logistic regression analysis. Race, sex, and level of education were evaluated as possible confounders. Results: A greater proportion of the patients in this study were Caucasian males. The only variable associated with compulsive behavior was age, with higher age having a protective effect (p = 0.0336). Disease duration (defined as time since the onset of symptoms), diagnosis duration (time since formal diagnosis), and level of education were significantly associated with dyskinesia inunivariate analysis (p =< 0.0001, <0.0001, 0.1236 respectively). However, diagnosis duration was the only variable significantly associated with dyskinesia in multivariate analysis (p = 0.0038), in addition to a borderline significant association when comparing individuals with graduate degree to those who had completed high school education or less (p = 0.0599), with a protective effect of higher education. Disease duration, diagnosis duration, and use of monoamineoxidase inhibitors were also significantly associated with motor fluctuations in the univariate analysis, while only diagnosis duration was significantly associated with motor fluctuations in multivariate analysis (p = 0.0035) with longer diagnosis duration associated with higher risk of motor fluctuations. Age, disease duration, and diagnosis duration were associated with an increased risk of hallucinations

show abstract

Section: Discussionsupporting

confidence: 92%

Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

Sisniega¹,

Madhusudhan²,

Rahmani³

et al. 2017

APD

View full text Add to dashboard Cite

show abstract

“…Three other PD co-morbid syndromes that have been the focus of recent reviews are visual hallucinations (Lenka et al., 2015), impulse control disorders (Jimenez-Urbieta et al, 2015; Vriend et al, 2014a), and dyskinesias (Jimenez-Urbieta et al, 2015). Note that Vriend et al (2014a) reviewed both depression and impulse control disorders in PD, while Jimenez-Urbieta et al (2015) reviewed both impulse control disorders and levodopa induced dyskinesias, as disorders with related neurobiological mechanisms.…”

Section: Neuroimaging Of Pdmentioning

confidence: 99%

“…Note that Vriend et al (2014a) reviewed both depression and impulse control disorders in PD, while Jimenez-Urbieta et al (2015) reviewed both impulse control disorders and levodopa induced dyskinesias, as disorders with related neurobiological mechanisms. Finally, co-morbid olfactory dysfunction, REM sleep behavior disorder, and tremor are also being investigated with neuroimaging (Tables 2, 3, 5).…”

Section: Neuroimaging Of Pdmentioning

confidence: 99%

Neuroimaging of Parkinson's disease: Expanding views

Weingarten

Sundman

Hickey

et al. 2015

Neuroscience & Biobehavioral Reviews

137

View full text Add to dashboard Cite

Advances in molecular and structural and functional neuroimaging are rapidly expanding the complexity of neurobiological understanding of Parkinson’s disease (PD). This review article begins with an introduction to PD neurobiology as a foundation for interpreting neuroimaging findings that may further lead to more integrated and comprehensive understanding of PD. Diverse areas of PD neuroimaging are then reviewed and summarized, including positron emission tomography, single photon emission computed tomography, magnetic resonance spectroscopy and imaging, transcranial sonography, magnetoencephalography, and multimodal imaging, with focus on human studies published over the last five years. These included studies on differential diagnosis, co-morbidity, genetic and prodromal PD, and treatments from L-DOPA to brain stimulation approaches, transplantation and gene therapies. Overall, neuroimaging has shown that PD is a neurodegenerative disorder involving many neurotransmitters, brain regions, structural and functional connections, and neurocognitive systems. A broad neurobiological understanding of PD will be essential for translational efforts to develop better treatments and preventive strategies. Many questions remain and we conclude with some suggestions for future directions of neuroimaging of PD.

show abstract

“…Genetic variants of serotonin receptors and polymorphisms for the dopaminergic, serotonergic, glutamate, and opioidergic systems have been related to the development of ICB in patients with PD (Comings & Blum, 2000; Ibanez, Blanco, Perez de Castro, Fernandez‐Piqueras, & Saiz‐Ruiz, 2003; Kraemmer et al., 2016; Le Foll, Gallo, Le Strat, Lu, & Gorwood, 2009; Lee, Jeon, Kim, & Park, 2012; Lee et al., 2009; Zainal Abidin et al., 2015). Thus, genetic variations in receptors, transporters, or enzymes of the catecholaminergic, serotonergic, glutamatergic, and opioid neurotransmission systems are potentially associated with ICD in PD (Jimenez‐Urbieta et al., 2015). …”

Section: Discussionmentioning

confidence: 99%

“…Being male has been reported as a risk factor for the development of ICB (Antonini et al., 2017; Weintraub, Koester, et al., 2010; Weintraub, et al., 2015; Zurowski & O'Brien, 2015). Both L‐DOPA induced dyskinesia (LID), and ICB can be induced by excessive dopaminergic stimulation in the motor or limbic territories of the striatum (Jimenez‐Urbieta et al., 2015; Rocha, Gago, Barbosa, Cavaleiro, & Laranjinha, 2015). Biundo et al.…”

Section: Discussionmentioning

confidence: 99%

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

et al. 2018

View full text Add to dashboard Cite

IntroductionImpulse control behaviors (ICBs) are impulsive–compulsive behaviors often associated with dopamine replacement therapy in Parkinson's disease (PD). Although remission can occur in ICB, only four reports on the ratio of remission and the persistence of ICB have been published, and the associated factors with ICB remission or persistence have been little known. Therefore, we conducted a longitudinal assessment of the remission, persistence, and development of ICB and those associated factors in patients with PD.MethodsWe retrospectively investigated a PD database at Aomori Prefectural Central Hospital, Japan. One hundred and forty‐eight patients with PD who could be followed up for 2 years were enrolled. ICB was assessed using the Questionnaire for Impulsive–Compulsive Disorders in Parkinson's disease. Motor severity (Hoehn and Yahr scale and United Parkinson's Disease Rating Scale), cognitive function (Mini–Mental State Examination), and other clinical variables (sex, age, onset age, disease duration, olfactory dysfunction, and dyskinesia) and medications used to treat PD were assessed. Univariate analyses were performed.ResultsSeven patients were excluded because of the exclusion criteria, and 141 patients were analyzed. Thirty patients (21.3%) had ICB at baseline, and these patients also had significantly higher use of pergolide. The ICB remission rate was 60%, the ICB persistence ratio was 40%, and the ICB development ratio was 12.6% over 2 years. Statistically, younger age and pergolide use were associated with ICB persistence. Being male, having dyskinesia, and rotigotine, entacapone, zonisamide, and istradefylline use were associated with ICB development.ConclusionThis study suggests that younger age and pergolide use may be the new associated factors with ICB persistence and that entacapone, zonisamide, and istradefylline use may be associated with the development of ICB. Drug profiles and medication practices in Japan may explain the association of these factors with ICB.

show abstract

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Cited by 39 publications

References 372 publications

Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

Neuroimaging of Parkinson's disease: Expanding views

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

Contact Info

Product

Resources

About